NRG Oncology Launches Phase 3 Trial for Innovative Bladder Cancer Treatment

Strategic Insights -

NRG Oncology has listed a Phase 3 clinical trial, ARCHER, designed to study the effectiveness of adaptive radiation and chemotherapy in treating muscle invasive bladder cancer. The trial aims to recruit 486 participants from the USA and compares the impact of ultra-hypofractionated radiation therapy with standard hypofractionation, alongside chemotherapy, on cancer treatment outcomes. This innovative approach involves delivering higher doses of radiation over a shorter period, potentially reducing side effects. The study also explores the use of chemotherapy drugs, including cisplatin, gemcitabine, and 5-fluorouracil, which work in different ways to stop the growth of tumor cells.

Key Takeaways:

  • The trial is designed to study the effectiveness of adaptive radiation and chemotherapy in treating muscle invasive bladder cancer.
  • The study will recruit 486 participants from the USA and will compare the impact of ultra-hypofractionated radiation therapy with standard hypofractionation.
  • The trial aims to determine whether ultra-hypofractionated radiation therapy is equally effective as hypofractionated therapy for patients with muscle invasive bladder cancer.
  • The study involves the use of chemotherapy drugs, including cisplatin, gemcitabine, and 5-fluorouracil, which work in different ways to stop the growth of tumor cells.
  • The trial is a Phase 3 study, indicating a high level of evidence and reliability in the results.
  • The study is being conducted by NRG Oncology, a non-profit organization dedicated to improving cancer treatments.

Statistics:

  • 486 participants will be recruited for the trial from the USA.
  • The trial is comparing the impact of ultra-hypofractionated radiation therapy with standard hypofractionation.
  • 3 chemotherapy drugs are being used in the study: cisplatin, gemcitabine, and 5-fluorouracil.
  • The trial is a Phase 3 study, indicating a high level of evidence and reliability in the results.
  • NRG Oncology is conducting the study.

Sources:

  • ClinicalTrials.gov

https://clinicaltrials.gov/study/NCT07097142